{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:03:16Z","timestamp":1770998596846,"version":"3.50.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1053\/j.seminoncol.2015.09.015","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T17:48:11Z","timestamp":1441648091000},"page":"134-145","source":"Crossref","is-referenced-by-count":15,"title":["Hereditary cancer syndromes as model systems for chemopreventive agent development"],"prefix":"10.1053","volume":"43","author":[{"given":"Farzana L.","family":"Walcott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Lubet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Calzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2015.09.015_bib1","first-page":"2699","article-title":"Approaches to prevention of epithelial cancer during the preneoplastic period","volume":"36","author":"Sporn","year":"1976","journal-title":"Cancer Res"},{"issue":"1-2","key":"10.1053\/j.seminoncol.2015.09.015_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/BD-2010-0308","article-title":"BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer","volume":"32","author":"Diaz-Cruz","year":"2010","journal-title":"Breast Dis"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib3","first-page":"1","article-title":"Concise handbook of familial cancer susceptibility syndromes\u2014second edition","volume":"38","author":"Lindor","year":"2008","journal-title":"J Natl Cancer Inst Mongr"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib4","first-page":"115","volume":"28","author":"Claus","year":"1993","journal-title":"The calculation of breast cancer risk for women with a first-degree family history of ovarian cancer. Breast Cancer Res Treat"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.015_bib5","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1073\/pnas.85.9.3044","article-title":"Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families","volume":"85","author":"Newman","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/GIM.0b013e3181d38f2f","article-title":"Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2","volume":"12","author":"Petrucelli","year":"2010","journal-title":"Genet Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ng1095-198","article-title":"The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals","volume":"11","author":"Struewing","year":"1995","journal-title":"Nat Genet"},{"issue":"20","key":"10.1053\/j.seminoncol.2015.09.015_bib8","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib9","first-page":"117","volume":"13","author":"Thorlacius","year":"1996","journal-title":"A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet"},{"issue":"5182","key":"10.1053\/j.seminoncol.2015.09.015_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng0396-333","article-title":"The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds","volume":"12","author":"Tavtigian","year":"1996","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib12","unstructured":"National Human Genome Research Institute. Breast Cancer Information Core. 2014 5\/16\/2014 [cited 2014 6\/27\/2014]; Available from: http:\/\/research.nhgri.nih.gov\/bic\/."},{"key":"10.1053\/j.seminoncol.2015.09.015_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"15","key":"10.1053\/j.seminoncol.2015.09.015_bib14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers","volume":"91","author":"Easton","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"6178","key":"10.1053\/j.seminoncol.2015.09.015_bib15","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"issue":"6178","key":"10.1053\/j.seminoncol.2015.09.015_bib16","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1126\/science.1252230","article-title":"Cancer suppression by the chromosome custodians, BRCA1 and BRCA2","volume":"343","author":"Venkitaraman","year":"2014","journal-title":"Science"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"issue":"26","key":"10.1053\/j.seminoncol.2015.09.015_bib18","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"25","key":"10.1053\/j.seminoncol.2015.09.015_bib20","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2010.12.002","article-title":"PARP inhibitor treatment in ovarian and breast cancer","volume":"35","author":"Weil","year":"2011","journal-title":"Curr Probl Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors-moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/8743","article-title":"Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation","volume":"22","author":"Xu","year":"1999","journal-title":"Nat Genet"},{"issue":"44","key":"10.1053\/j.seminoncol.2015.09.015_bib25","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.015_bib26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/1940-6207.CAPR-14-0047","article-title":"The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice","volume":"7","author":"To","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib27","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/bcr2850","article-title":"Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice","volume":"13","author":"Burga","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1940-6207.CAPR-11-0359","article-title":"CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice","volume":"5","author":"Kim","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7326\/0003-4819-71-4-747","article-title":"Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?","volume":"71","author":"Li","year":"1969","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1053\/j.seminoncol.2015.09.015_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJM199205143262002","article-title":"Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms","volume":"326","author":"Malkin","year":"1992","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.015_bib31","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1947601911413466","article-title":"Li-fraumeni syndrome","volume":"2","author":"Malkin","year":"2011","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.015_bib33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S1470-2045(09)70089-0","article-title":"Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?","volume":"10","author":"Achatz","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.21151","article-title":"Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect","volume":"31","author":"Garritano","year":"2010","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib35","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/humu.22559","article-title":"Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome","volume":"35","author":"Kamihara","year":"2014","journal-title":"Hum Mutat"},{"issue":"23","key":"10.1053\/j.seminoncol.2015.09.015_bib36","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1016\/j.bmc.2012.09.035","article-title":"Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy","volume":"20","author":"Gardner","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib37","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/srep04223","article-title":"Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations","volume":"4","author":"Xu","year":"2014","journal-title":"Sci Rep"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.015_bib38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/jmg.2008.057570","article-title":"Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families","volume":"45","author":"Bougeard","year":"2008","journal-title":"J Med Genet"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/0970-9371.101188","article-title":"Author\u2019s response","volume":"29","author":"Kumar","year":"2012","journal-title":"J Cytol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","article-title":"Li-Fraumeni syndrome: cancer risk assessment and clinical management","volume":"11","author":"McBride","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib41","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","article-title":"Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort","volume":"133","author":"Masciari","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib43","doi-asserted-by":"crossref","first-page":"D962","DOI":"10.1093\/nar\/gks1033","article-title":"The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis","volume":"41","author":"Leroy","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"5780","key":"10.1053\/j.seminoncol.2015.09.015_bib44","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1126863","article-title":"p53 regulates mitochondrial respiration","volume":"312","author":"Matoba","year":"2006","journal-title":"Science"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib45","doi-asserted-by":"crossref","first-page":"a001040","DOI":"10.1101\/cshperspect.a001040","article-title":"p53 regulation of metabolic pathways","volume":"2","author":"Gottlieb","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib46","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1089\/ars.2010.3650","article-title":"p53, aerobic metabolism, and cancer","volume":"15","author":"Lago","year":"2011","journal-title":"Antioxid Redox Signal"},{"issue":"43","key":"10.1053\/j.seminoncol.2015.09.015_bib47","doi-asserted-by":"crossref","first-page":"17356","DOI":"10.1073\/pnas.1310908110","article-title":"Mitochondrial disulfide relay mediates translocation of p53 and partitions its subcellular activity","volume":"110","author":"Zhuang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5930","key":"10.1053\/j.seminoncol.2015.09.015_bib48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09513590400004736","article-title":"Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study","volume":"19","author":"Sahin","year":"2004","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/00016340902835919","article-title":"Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization","volume":"88","author":"Kumbak","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.015_bib52","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"14","key":"10.1053\/j.seminoncol.2015.09.015_bib53","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth","volume":"67","author":"Buzzai","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.015_bib54","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: the end of the beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci (Lond)"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.015_bib56","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1214091","article-title":"Increased oxidative metabolism in the Li-Fraumeni syndrome","volume":"368","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib57","unstructured":"A pilot study of metformin in patients with a diagnosis of Li-Fraumeni syndrome. Cited 2015; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01981525?term=Li+Fraumeni&recr=Open&rank=4."},{"key":"10.1053\/j.seminoncol.2015.09.015_bib58","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nrc2731","article-title":"20 years of studying P53 function in genetically engineered mice","volume":"9","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-540-69297-3_13","article-title":"Prevention of ER-negative breast cancer","volume":"181","author":"Li","year":"2009","journal-title":"Recent Results Cancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.015_bib60","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1940-6207.CAPR-13-0182","article-title":"A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease","volume":"6","author":"Disis","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01902140490495499","article-title":"Mouse models incorporating alterationsin the major tumor suppressor genes P53 and P16: their use in screening for potential carcinogens, developing further mouse models and screening for chemopreventive and chemotherapeutic agents","volume":"31","author":"Lubet","year":"2005","journal-title":"Exp Lung Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib62","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome","volume":"119","author":"Lang","year":"2004","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib63","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1067\/j.cpsurg.2005.02.003","article-title":"Hereditary colorectal cancer\u2014part II","volume":"42","author":"Merg","year":"2005","journal-title":"Curr Probl Surg"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-4-22","article-title":"Familial adenomatous polyposis","volume":"4","author":"Half","year":"2009","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib66","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1572-0241.2004.04115.x","article-title":"Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis","volume":"99","author":"Attard","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1572-0241.2002.05461.x","article-title":"Gastric polyps in pediatrics: an 18-year hospital-based analysis","volume":"97","author":"Attard","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"7-8","key":"10.1053\/j.seminoncol.2015.09.015_bib68","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0959-8049(95)00171-E","article-title":"Upper intestinal surveillance in familial adenomatous polyposis","volume":"31A","author":"Debinski","year":"1995","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1067\/j.cpsurg.2005.01.004","article-title":"Hereditary colon cancer\u2014part I","volume":"42","author":"Merg","year":"2005","journal-title":"Curr Probl Surg"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib70","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.suc.2006.05.007","article-title":"Clinical implications of our advancing knowledge of colorectal cancer genetics: inherited syndromes, prognosis, prevention, screening and therapeutics","volume":"86","author":"Gryfe","year":"2006","journal-title":"Surg Clin North Am"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.ejhg.5201088","article-title":"Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis","volume":"12","author":"Aretz","year":"2004","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib72","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF02281864","article-title":"Attenuated familial adenomatous polyposis due to a mutation in the 3\u2019 part of the APC gene. A clue for understanding the function of the APC protein","volume":"97","author":"Friedl","year":"1996","journal-title":"Hum Genet"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1023286520725","article-title":"Attenuated familial adenomatous polyposis (AFAP). A review of the literature","volume":"2","author":"Knudsen","year":"2003","journal-title":"Fam Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib74","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/(SICI)1098-1004(1998)11:6<450::AID-HUMU5>3.0.CO;2-P","article-title":"A family with attenuated familial adenomatous polyposis due to a mutation in the alternatively spliced region of APC exon 9","volume":"11","author":"Young","year":"1998","journal-title":"Hum Mutat"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib75","first-page":"705","volume":"96","author":"van der Luijt","year":"1995","journal-title":"APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/hmg\/3.1.53","article-title":"Regionally clustered APC mutations are associated with a severe phenotype and occur at a high frequency in new mutation cases of adenomatous polyposis coli","volume":"3","author":"Gayther","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib77","first-page":"629","volume":"343","author":"Caspari","year":"1994","journal-title":"Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. Lancet"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.015_bib78","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jmg.2007.052506","article-title":"High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome","volume":"44","author":"Aretz","year":"2007","journal-title":"J Med Genet"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/path.1272","article-title":"Colorectal tumourigenesis in carriers of the APC I1307K variant: lone gunman or conspiracy?","volume":"199","author":"Sieber","year":"2003","journal-title":"J Pathol"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.015_bib80","first-page":"7595","article-title":"Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway","volume":"63","author":"Lipton","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/ng828","article-title":"Inherited variants of MYH associated with somatic G:C\u2192T:A mutations in colorectal tumors","volume":"30","author":"Al-Tassan","year":"2002","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib82","first-page":"337","volume":"4","author":"Caspari","year":"1995","journal-title":"Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib83","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cgh.2006.12.014","article-title":"Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis","volume":"5","author":"Nieuwenhuis","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4-5","key":"10.1053\/j.seminoncol.2015.09.015_bib84","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.bpg.2011.08.002","article-title":"Chemoprevention in familial adenomatous polyposis","volume":"25","author":"Kim","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"26","key":"10.1053\/j.seminoncol.2015.09.015_bib85","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.seminoncol.2015.09.015_bib86","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1073\/pnas.93.15.7950","article-title":"Apoptosis and APC in colorectal tumorigenesis","volume":"93","author":"Morin","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1055-9965.920.13.6","article-title":"Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients","volume":"13","author":"Sinicrope","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-3-642-30331-9_8","article-title":"Nutritional agents with anti-inflammatory properties in chemoprevention of colorectal neoplasia","volume":"191","author":"Hull","year":"2013","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib89","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.hoc.2010.08.011","article-title":"Mouse models of inherited cancer syndromes","volume":"24","author":"Jahid","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.015_bib90","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/1940-6207.CAPR-11-0166","article-title":"Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention","volume":"4","author":"Fischer","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"18","key":"10.1053\/j.seminoncol.2015.09.015_bib91","first-page":"5040","article-title":"The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis","volume":"60","author":"Jacoby","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib93","unstructured":"A clinical trial of COX and EGFR inhibition in Familial Adenomatous Polyposis patients (FAPEST). 2014 [cited 2014 11\/4\/2014]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01187901?term=A+clinical+trial+of+COX+and+EGFR+inhibition+in+Familial+Adenomatous+Polyposis+patients&rank=1."},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib94","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1534\/genetics.108.091967","article-title":"The pleiotropic phenotype of Apc mutations in the mouse: allele specificity and effects of the genetic background","volume":"180","author":"Halberg","year":"2008","journal-title":"Genetics"},{"issue":"31","key":"10.1053\/j.seminoncol.2015.09.015_bib95","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.3748\/wjg.v12.i31.4943","article-title":"Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term","volume":"12","author":"Jass","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib96","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/archinte.1913.00070050063006","article-title":"Heredity with reference to carcinoma: as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913","volume":"12","author":"Warthin","year":"1913","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib97","first-page":"206","volume":"117","author":"Lynch","year":"1966","journal-title":"Hereditary factors in cancer: study of two large midwestern kindreds"},{"issue":"6468","key":"10.1053\/j.seminoncol.2015.09.015_bib98","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/368258a0","article-title":"Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer","volume":"368","author":"Bronner","year":"1994","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib99","first-page":"1625","volume":"263","author":"Papadopoulos","year":"1994","journal-title":"Mutation of a mutL homolog in hereditary colon cancer. Science"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib100","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0092-8674(93)90330-S","article-title":"Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer","volume":"75","author":"Leach","year":"1993","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib101","first-page":"271","volume":"17","author":"Miyaki","year":"1997","journal-title":"Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib102","first-page":"3920","volume":"57","author":"Akiyama","year":"1997","journal-title":"Germ-line mutation of the hMSH6\/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib103","first-page":"75","volume":"371","author":"Nicolaides","year":"1994","journal-title":"Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib104","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2005.10.052","article-title":"Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome)","volume":"130","author":"Hendriks","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ng.283","article-title":"Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3\u2019 exons of TACSTD1","volume":"41","author":"Ligtenberg","year":"2009","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib106","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/humu.20942","article-title":"Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome","volume":"30","author":"Kovacs","year":"2009","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.015_bib107","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/gutjnl-2012-304356","article-title":"Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts","volume":"62","author":"Vasen","year":"2013","journal-title":"Gut"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/3-540-26980-0_2","article-title":"Application of genetics to the prevention of colorectal cancer","volume":"166","author":"Hooper","year":"2005","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib109","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.gastro.2005.05.011","article-title":"Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset","volume":"129","author":"Hampel","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10689-004-5811-3","article-title":"The incidence of Lynch syndrome","volume":"4","author":"de la Chapelle","year":"2005","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib111","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/1078-0432.CCR-06-1256","article-title":"Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors","volume":"13","author":"Aaltonen","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.015_bib112","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2000.18.11.2193","article-title":"Population-based molecular detection of hereditary nonpolyposis colorectal cancer","volume":"18","author":"Salovaara","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1940-6207.CAPR-10-0345","article-title":"The search for unaffected individuals with Lynch syndrome: do the ends justify the means?","volume":"4","author":"Hampel","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.015_bib114","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1054\/bjoc.2000.1520","article-title":"Population carrier frequency of hMSH2 and hMLH1 mutations","volume":"83","author":"Dunlop","year":"2000","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib115","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/gast.2001.28634","article-title":"HNPCC: an uncommon but important diagnosis","volume":"121","author":"Terdiman","year":"2001","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.015_bib116","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1053\/j.gastro.2010.04.024","article-title":"Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.015_bib117","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra012242","article-title":"Hereditary colorectal cancer","volume":"348","author":"Lynch","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10689-007-9164-6","article-title":"Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)","volume":"7","author":"Geary","year":"2008","journal-title":"Fam Cancer"},{"issue":"Suppl 2","key":"10.1053\/j.seminoncol.2015.09.015_bib119","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2007.03479.x","article-title":"Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer)","volume":"26","author":"Vasen","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2015.09.015_bib120","doi-asserted-by":"crossref","unstructured":"Kastrinos F. et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790-5.","DOI":"10.1001\/jama.2009.1529"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib121","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djh034","article-title":"Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability","volume":"96","author":"Umar","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.015_bib122","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib123","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1470-2045(10)70265-5","article-title":"Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study","volume":"12","author":"Kempers","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.015_bib124","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.5858\/2005-129-1385-TFDDMR","article-title":"Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide","volume":"129","author":"Burgart","year":"2005","journal-title":"Arch Pathol Lab Med"},{"issue":"9809","key":"10.1053\/j.seminoncol.2015.09.015_bib125","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1053\/j.seminoncol.2015.09.015_bib126","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","article-title":"Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome","volume":"359","author":"Burn","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2015.09.015_bib127","doi-asserted-by":"crossref","first-page":"11301","DOI":"10.1073\/pnas.95.19.11301","article-title":"Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection","volume":"95","author":"Ruschoff","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.015_bib128","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1158\/0008-5472.CAN-07-2562","article-title":"Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells","volume":"67","author":"McIlhatton","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.AOG.0000154885.44002.ae","article-title":"Gynecologic cancer as a \"sentinel cancer\" for women with hereditary nonpolyposis colorectal cancer syndrome","volume":"105","author":"Lu","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.015_bib130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1158\/1940-6207.CAPR-13-0020","article-title":"Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome","volume":"6","author":"Lu","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib131","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1158\/1940-6207.CAPR-10-0319","article-title":"Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model","volume":"4","author":"McIlhatton","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib132","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CCO.0000000000000098","article-title":"Aspirin in gastrointestinal oncology: new data on an old friend","volume":"26","author":"Langley","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.015_bib133","doi-asserted-by":"crossref","first-page":"e68817","DOI":"10.1371\/journal.pone.0068817","article-title":"Genotype directed therapy in murine mismatch repair deficient tumors","volume":"8","author":"Kucherlapati","year":"2013","journal-title":"PLoS One"},{"issue":"4-5","key":"10.1053\/j.seminoncol.2015.09.015_bib134","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bpg.2011.10.012","article-title":"Chemoprevention\u2014history and general principles","volume":"25","author":"Wu","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.015_bib135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.juro.2010.10.078","article-title":"Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer","volume":"185","author":"Reed","year":"2011","journal-title":"J Urol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.015_bib136","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/1940-6207.CAPR-10-0200","article-title":"Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen","volume":"4","author":"Svatek","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.015_bib137","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1053\/j.seminoncol.2010.05.012","article-title":"Drug development for cancer chemoprevention: focus on molecular targets","volume":"37","author":"Johnson","year":"2010","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.015_bib138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.015_bib139","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.015_bib140","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T21:08:43Z","timestamp":1691960923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775415001803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0093775415001803"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.015","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}